Changes in weight secondary to improved odor perception in chronic rhinosinusitis with nasal polyps’ patients treated with Dupilumab
European Archives of Oto-Rhino-Laryngology · 2025
DOI: 10.1007/s00405-024-09021-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2025. Verfasst von Cecilia Rosso und 7 weiteren Autor:innen. Beteiligte Einrichtung: Otorhinolaryngology Unit, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milan, Italy. rosso.cecilia1@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nasal Polyps, Olfactory Perception, Rhinosinusitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Milano.
Abstract (Originalsprache)
Purpose
The advent of biologic therapies, notably Dupilumab, has transformed therapeutic approaches to nasal polyposis. This retrospective multicentric study aimed to investigate weight changes in CRSwNP patients undergoing Dupilumab treatment and explore potential correlations with olfactory improvement.
Methods
Ninety-six patients with CRSwNP were followed for at least 12 months, with assessments including BMI (Body Mass Index), olfactory function, and disease severity.
Results
Significant increases in BMI and olfactory perception were observed after 1 year of Dupilumab treatment ( p < .001). Subgroup analysis showed that patients with hyposmia and normosmia at T12 (1-year follow up) experienced significant weight gain ( p < .001) alongside improved olfaction (both p < .001). Conversely, patients with anosmia after 1 year of therapy and also patients with stable or worsened olfaction did not show significant BMI changes (respectively p = .201 and p = .107).
Conclusion
While these findings suggest a correlation between olfactory improvement and weight gain/BMI, factors like improved nasal airflow and corticosteroid cessation under Dupilumab treatment may also influence weight in CRPwNP patients. The study highlights the need for further research to elucidate the causal relationship and long-term implications of Dupilumab-induced olfactory improvement on weight regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otorhinolaryngology Unit, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milan, Italy. rosso.cecilia1@gmail.com.
- , via Antonio di Rudinì 8, ASST Santi Polo e Carlo, Milan, Italy. rosso.cecilia1@gmail.com.
- Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
- Otorhinolaryngology Unit, Department of Surgical Sciences, University of Turin, Turin, Italy.
- Department of Otolaryngology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043, Italy.
- Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Förderung
- Università degli Studi di Milano
Zitieren
APA
Rosso, C., De Corso, E., Urbanelli, A., Fadda, G., Saibene, A. M., Ferella, F., Spanu, C., & Pipolo, C. (2025). Changes in weight secondary to improved odor perception in chronic rhinosinusitis with nasal polyps’ patients treated with Dupilumab. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-09021-0
Vancouver
Rosso C, De Corso E, Urbanelli A, Fadda G, Saibene AM, Ferella F, et al. Changes in weight secondary to improved odor perception in chronic rhinosinusitis with nasal polyps’ patients treated with Dupilumab. European Archives of Oto-Rhino-Laryngology. 2025. doi:10.1007/s00405-024-09021-0
BibTeX
@article{Rosso2025,
author = {Rosso, Cecilia and De Corso, Eugenio and Urbanelli, Anastasia and Fadda, Gianluca and Saibene, Alberto Maria and Ferella, Francesco and Spanu, Camilla and Pipolo, Carlotta},
title = {Changes in weight secondary to improved odor perception in chronic rhinosinusitis with nasal polyps’ patients treated with Dupilumab},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2025},
doi = {10.1007/s00405-024-09021-0}
}
EUVIMED